1. Glycodeoxycholic acid as alternative treatment in 3β-hydroxy-Δ5-C27-steroid-oxidoreductase: a case report
- Author
-
S. Majait, F. M. Vaz, E. Marleen Kemper, A. H. Bootsma, A. K. Groen, M. Nieuwdorp, and Maarten R. Soeters
- Subjects
3β-HSD ,bile acid defect ,glycine-conjugated deoxycholic acid ,FXR ligand ,postprandial ,Pediatrics ,RJ1-570 - Abstract
Background3β-hydroxy-Δ5-C27-steroid-oxidoreductase (3β-HSD) deficiency is a bile acid synthesis disorder that leads to the absence of normal primary bile acids and the accumulation of abnormal bile acids. This results in cholestatic jaundice, fat-soluble vitamin deficiency, acholic or fatty stools and failure to thrive. Bile acid supplementation is used to treat 3β-HSD-deficiency and its symptoms.MethodsThis report details the case of a 28-year-old woman diagnosed with 3β-HSD-deficiency, who was treated with glycine-conjugated deoxycholic acid (gDCA).ResultsgDCA treatment successfully restored normal bile acid levels, improved body weight by reducing fat malabsorption, and was well-tolerated with no observed liver problems or side effects.ConclusionsAs a potent FXR ligand, gDCA might exert its action through FXR activation leading to bile acid synthesis regulation.
- Published
- 2024
- Full Text
- View/download PDF